Lv51
1510 积分 2024-07-16 加入
Targeting TL1A and DR3: the new frontier of anti-cytokine therapy in IBD
3天前
已完结
AI-designed PNA-peptide chimera overcomes suboptimal binding for dual inhibition of viral RdRp
6天前
已完结
RNAi-based drug design: considerations and future directions
11天前
已完结
Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials
1个月前
已完结
Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study
1个月前
已完结
Lerodalcibep and evolocumab for the treatment of homozygous familial hypercholesterolaemia with PCSK9 inhibition (LIBerate-HoFH): a phase 3, randomised, open-label, crossover, non-inferiority trial
1个月前
已完结
Efficacy and safety of ongericimab in Chinese statin-intolerant patients with primary hypercholesterolemia or mixed dyslipidemia: a randomized, placebo-controlled phase 3 trial
1个月前
已完结
Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia
1个月前
已完结
Discovery of a Novel Dual-Targeting KRAS G12D /HDAC Peptide Inhibitor for the Treatment of Pancreatic Cancer
1个月前
已完结
TNF receptors: Structure-function relationships and therapeutic targeting strategies
1个月前
已完结
皖公网安备34019202002308
